Autolus Therapeutics (AUTL) Total Non-Current Liabilities (2020 - 2026)

Autolus Therapeutics (AUTL) has 6 years of Total Non-Current Liabilities data on file, last reported at $410.5 million in Q4 2025.

• Quarterly Total Non-Current Liabilities rose 15.63% year-over-year to $410.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $410.5 million (up 15.63% YoY) and the FY2025 annual result came in at $410.5 million, up 15.63% from the prior year.
• Total Non-Current Liabilities improved to $410.5 million in Q4 2025, from $396.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $410.5 million in Q4 2025 to a low of $92.1 million in Q4 2021.
• A 5-year average of $258.0 million and a median of $263.6 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2021 — Total Non-Current Liabilities advanced 9.39% — and 2023, when it soared 123.01%.
• Tracing AUTL's Total Non-Current Liabilities over 5 years: stood at $92.1 million in 2021, then surged by 107.88% to $191.5 million in 2022, then surged by 37.64% to $263.6 million in 2023, then surged by 34.69% to $355.0 million in 2024, then advanced by 15.63% to $410.5 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $410.5 million (Q4 2025), $396.0 million (Q3 2025), and $374.0 million (Q2 2025), per Business Quant data.